Celgene Corp. (CELG)

• Annual Data
• Quarterly Data

Celgene Corp., Consolidated Statement of Financial Position, Liabilities and Stockholders’ Equity

US$ in millions

		Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Short-term borrowings and current portion of long-term debt
	Accounts payable
	Rebates, distributor chargebacks and distributor services
	Compensation
	Clinical trial costs and grants
	Litigation-related loss contingency
	Interest
	Sales, use, value added, and other taxes
	Milestones payable
	Success payment liability
	Short-term contingent consideration and success payments
	Royalties, license fees and collaboration agreements
	Deferred tax liability
	Other
	Accrued expenses and other current liabilities
	Income taxes payable
	Current portion of deferred revenue
	Current liabilities
	Deferred revenue, net of current portion
	Income taxes payable
	Deferred income tax liabilities
	Other non-current tax liabilities
	Contingent consideration
	Deferred compensation and long-term incentives
	Contingent value rights
	Derivative contracts
	Other
	Other non-current liabilities
	Long-term debt, net of discount, excluding current portion
	Non-current liabilities
	Total liabilities
	Preferred stock, $.01 par value per share; none outstanding
	Common stock, $.01 par value per share
	Common stock in treasury, at cost
	Additional paid-in capital
	Retained earnings
	Accumulated other comprehensive income (loss)
	Stockholders’ equity
	Total liabilities and stockholders’ equity

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20).